Fundamental analysis · SEC EDGAR · TTM through 31/03/2026

Fundamental analysis of Merck & Co., Inc.

MRK · NYSE · Pharmaceutical Preparations

Fundamental quality

REASONABLE

64

out of 100

Breakdown by area

I.GrowthEPS: -13.6% · Revenue: 3.2%
18
II.ProfitabilityNet margin: 13.6% · ROE: 19.5%
78
III.Financial healthFCF: 21.5%
95

Source: SEC EDGAR · TTM through 31/03/2026

Reading the numbers

On average over recent years, earnings per share fell 13.6% a year and revenue advanced 3.2% a year.

On profitability, Merck & Co., Inc. shows a net margin of 13.6%, an ROE of 19.5%.

Its financial health shows a free cash flow margin of 21.5%.

Adding up growth, profitability and financial strength, the traffic light gives MRK a fundamental quality of 64 out of 100. To also know whether it's cheap or expensive, the price is missing: enter it in the tool and you'll get the valuation verdict (P/E against its sector).

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Is Merck & Co., Inc. cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →
Advertising

Where to buy Merck & Co., Inc.?

Brokers you can use to invest in U.S. and European stocks.

Compare the brokers →